Genprex to Present Parallel Gene Delivery Approaches for Diabetes Therapy Development
Key Points
- Genprex will present AAV and lipid-based gene delivery work for diabetes at the Future of Cell and Gene Therapy Symposium on November 17–18.
- Its AAV candidate delivers the Pdx1 and MafA genes to help reprogram pancreatic cells toward insulin production for Type 1 and Type 2 diabetes.
- Both approaches remain preclinical as Genprex evaluates manufacturing and development requirements ahead of IND-enabling studies.
Genprex will soon share progress on two gene delivery strategies under evaluation for its diabetes gene therapy program at the upcoming Future of Cell and Gene Therapy Symposium on November 17–18.
Pier-Anne Lachance, Ph.D., Genprex’s senior director of Quality Control and Product Development, will present “Building the Future of Diabetes Gene Therapy: Lessons from Parallel AAV and Lipid-Based Development Programs.” Her presentation will examine the company’s work with both adeno-associated virus (AAV) and non-viral lipid-based delivery technologies, with an emphasis on the scientific, manufacturing and product development challenges associated with each approach.
The presentation will also address how experience gained from developing the two platforms could guide formulation and process optimization, as well as future development decisions for the company’s diabetes program.
“Advancing gene therapies requires not only innovative science, but also a disciplined approach to delivery, manufacturing and product development,” says Ryan Confer, president and CEO of Genprex. He notes that evaluating both viral and non-viral delivery systems allows the company to address key development considerations as it works to advance its diabetes program.
Genprex is pursuing gene therapy approaches intended to restore insulin-producing capabilities in patients with both Type 1 and Type 2 diabetes. Its AAV-based candidate is designed to deliver the Pdx1 and MafA genes to the pancreas. These genes are intended to help reprogram pancreatic cells toward an insulin-producing function.
Alongside the viral approach, the company is investigating a lipid-based, non-viral delivery system that could provide greater flexibility in administration, including the possibility of repeat dosing. Both strategies remain in preclinical development. Genprex is evaluating the approaches in parallel to better understand their respective development and manufacturing requirements and determine how best to optimize the program ahead of planned investigational new drug (IND)-enabling studies.
For more information, visit www.genprex.com.
Total Page Views: 4
